Fly News Breaks for July 15, 2019
Jul 15, 2019 | 16:15 EDT
Oppenheimer analyst Jay Olson initiated Viking Therapeutics with an Outperform rating and $12 price target, citing his view that the company has a validated approach to nonalcoholic steatohepatitis, or NASH. He estimates lead asset VK2809 can have total worldwide peak unadjusted sales of $2.2B and he sets a 35% probability of success for the drug.
News For VKTX From the Last 2 Days
There are no results for your query VKTX